Literature DB >> 7962538

Acute intermittent porphyria: identification and expression of exonic mutations in the hydroxymethylbilane synthase gene. An initiation codon missense mutation in the housekeeping transcript causes "variant acute intermittent porphyria" with normal expression of the erythroid-specific enzyme.

C H Chen1, K H Astrin, G Lee, K E Anderson, R J Desnick.   

Abstract

Acute intermittent porphyria (AIP), an autosomal dominant inborn error, results from the half-normal activity of the heme biosynthetic enzyme, hydroxymethylbilane synthase (EC 4.3.1.8). Diagnosis of AIP heterozygotes is essential to prevent acute, life-threatening neurologic attacks by avoiding various precipitating factors. Since biochemical diagnosis is problematic, the identification of hydroxymethylbilane synthase mutations has facilitated the detection of AIP heterozygotes. Molecular analyses of unrelated AIP patients revealed six exonic mutations: an initiating methionine to isoleucine substitution (M1I) in a patient with variant AIP, which precluded translation of the housekeeping, but not the erythroid-specific isozyme; four missense mutations in classical AIP patients, V93F, R116W, R201W, C247F; and a nonsense mutation W283X in a classical AIP patient, which truncated the housekeeping and erythroid-specific isozymes. Each mutation was confirmed in genomic DNA from family members. The W283X lesion was found in another unrelated AIP family. Expression of each mutation in Escherichia coli revealed that R201W, C247F, and W283X had residual activity. In vitro transcription/translation studies indicated that the M1I allele produced only the erythroid-specific enzyme, while the other mutant alleles encoded both isozymes. These mutations provide insight into the molecular pathology of classic and variant AIP and facilitate molecular diagnosis in AIP families.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7962538      PMCID: PMC294605          DOI: 10.1172/JCI117543

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  62 in total

1.  A MspI polymorphism for the human porphobilinogen deaminase gene.

Authors:  D H Llewellyn; N A Kalsheker; G H Elder; P R Harrison; S Chretien; M Goossens
Journal:  Nucleic Acids Res       Date:  1987-02-11       Impact factor: 16.971

2.  Genetic heterogeneity in acute intermittent porphyria: characterisation and frequency of porphobilinogen deaminase mutations in Finland.

Authors:  P Mustajoki; R J Desnick
Journal:  Br Med J (Clin Res Ed)       Date:  1985-08-24

3.  Variant of acute intermittent porphyria with normal erythrocyte uroporphyrinogen-I-synthase activity.

Authors:  P Mustajoki; R Tenhunen
Journal:  Eur J Clin Invest       Date:  1985-10       Impact factor: 4.686

4.  Acute intermittent porphyria: characterization of a novel mutation in the structural gene for porphobilinogen deaminase. Demonstration of noncatalytic enzyme intermediates stabilized by bound substrate.

Authors:  R J Desnick; L T Ostasiewicz; P A Tishler; P Mustajoki
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

5.  A PstI polymorphism for the human porphobilinogen deaminase gene (PBG).

Authors:  J S Lee; M Anvret
Journal:  Nucleic Acids Res       Date:  1987-08-11       Impact factor: 16.971

6.  Red blood cell porphobilinogen deaminase in the evaluation of acute intermittent porphyria.

Authors:  C A Pierach; M K Weimer; R A Cardinal; I C Bossenmaier; J R Bloomer; J R Blommer
Journal:  JAMA       Date:  1987-01-02       Impact factor: 56.272

7.  Detection of eleven mutations causing acute intermittent porphyria using denaturing gradient gel electrophoresis.

Authors:  X F Gu; F de Rooij; G Voortman; K Te Velde; J C Deybach; Y Nordmann; B Grandchamp
Journal:  Hum Genet       Date:  1994-01       Impact factor: 4.132

8.  Tissue-specific expression of porphobilinogen deaminase. Two isoenzymes from a single gene.

Authors:  B Grandchamp; H De Verneuil; C Beaumont; S Chretien; O Walter; Y Nordmann
Journal:  Eur J Biochem       Date:  1987-01-02

9.  Recurrence risk estimation of acute intermittent porphyria based on analysis of porphobilinogen deaminase activity: a Bayesian approach.

Authors:  C Bonaïti-Pellié; L Phung; Y Nordmann
Journal:  Am J Med Genet       Date:  1984-12

10.  Molecular cloning and complete primary sequence of human erythrocyte porphobilinogen deaminase.

Authors:  N Raich; P H Romeo; A Dubart; D Beaupain; M Cohen-Solal; M Goossens
Journal:  Nucleic Acids Res       Date:  1986-08-11       Impact factor: 16.971

View more
  19 in total

1.  Identification and expression of mutations in the hydroxymethylbilane synthase gene causing acute intermittent porphyria (AIP).

Authors:  C Solis; I Lopez-Echaniz; D Sefarty-Graneda; K H Astrin; R J Desnick
Journal:  Mol Med       Date:  1999-10       Impact factor: 6.354

2.  Molecular epidemiology and diagnosis of PBG deaminase gene defects in acute intermittent porphyria.

Authors:  H Puy; J C Deybach; J Lamoril; A M Robreau; V Da Silva; L Gouya; B Grandchamp; Y Nordmann
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

3.  Identification and characterization of 40 novel hydroxymethylbilane synthase mutations that cause acute intermittent porphyria.

Authors:  Brenden Chen; Constanza Solis-Villa; Angelika L Erwin; Manisha Balwani; Irina Nazarenko; John D Phillips; Robert J Desnick; Makiko Yasuda
Journal:  J Inherit Metab Dis       Date:  2019-01       Impact factor: 4.982

4.  Acute Intermittent Porphyria: Predicted Pathogenicity of HMBS Variants Indicates Extremely Low Penetrance of the Autosomal Dominant Disease.

Authors:  Brenden Chen; Constanza Solis-Villa; Jörg Hakenberg; Wanqiong Qiao; Ramakrishnan R Srinivasan; Makiko Yasuda; Manisha Balwani; Dana Doheny; Inga Peter; Rong Chen; Robert J Desnick
Journal:  Hum Mutat       Date:  2016-09-05       Impact factor: 4.878

5.  Homozygous hydroxymethylbilane synthase knock-in mice provide pathogenic insights into the severe neurological impairments present in human homozygous dominant acute intermittent porphyria.

Authors:  Makiko Yasuda; Lin Gan; Brenden Chen; Chunli Yu; Jinglan Zhang; Miguel A Gama-Sosa; Daniela D Pollak; Stefanie Berger; John D Phillips; Winfried Edelmann; Robert J Desnick
Journal:  Hum Mol Genet       Date:  2019-06-01       Impact factor: 6.150

Review 6.  Porphobilinogen deaminase gene structure and molecular defects.

Authors:  J C Deybach; H Puy
Journal:  J Bioenerg Biomembr       Date:  1995-04       Impact factor: 2.945

7.  Familial porphyria cutanea tarda: characterization of seven novel uroporphyrinogen decarboxylase mutations and frequency of common hemochromatosis alleles.

Authors:  M Mendez; L Sorkin; M V Rossetti; K H Astrin; A M del C Batlle; V E Parera; G Aizencang; R J Desnick
Journal:  Am J Hum Genet       Date:  1998-11       Impact factor: 11.025

8.  Four mutations in the porphobilinogen deaminase gene in patients with acute intermittent porphyria.

Authors:  G Lundin; J Hashemi; Y Floderus; S Thunell; E Sagen; A Laegreid; W Wassif; T Peters; M Anvret
Journal:  J Med Genet       Date:  1995-12       Impact factor: 6.318

9.  AAV8-mediated gene therapy prevents induced biochemical attacks of acute intermittent porphyria and improves neuromotor function.

Authors:  Makiko Yasuda; David F Bishop; Mary Fowkes; Seng H Cheng; Lin Gan; Robert J Desnick
Journal:  Mol Ther       Date:  2009-10-27       Impact factor: 11.454

10.  Human hydroxymethylbilane synthase: Molecular dynamics of the pyrrole chain elongation identifies step-specific residues that cause AIP.

Authors:  Navneet Bung; Arijit Roy; Brenden Chen; Dibyajyoti Das; Meenakshi Pradhan; Makiko Yasuda; Maria I New; Robert J Desnick; Gopalakrishnan Bulusu
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.